Exclusion ofBRAFV599E as a melanoma susceptibility mutation
Open Access
- 2 June 2003
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 106 (1), 78-80
- https://doi.org/10.1002/ijc.11199
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- High Frequency of Multiple Melanomas and Breast and Pancreas Carcinomas in CDKN2A Mutation-Positive Melanoma FamiliesJNCI Journal of the National Cancer Institute, 2000
- Characterization of ligurian melanoma families and risk of occurrence of other neoplasiaInternational Journal of Cancer, 1999
- CDKN2A Variants in a Population-Based Sample of Queensland Families With MelanomaJNCI Journal of the National Cancer Institute, 1999
- Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group [published erratum appears in Hum Mol Genet 1998 May;7(5):941]Human Molecular Genetics, 1998
- Germline Mutations of the CDKN2 Gene in UK Melanoma FamiliesHuman Molecular Genetics, 1997
- Screening for CDKN2A mutations in hereditary melanoma.JNCI Journal of the National Cancer Institute, 1997
- Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population.Proceedings of the National Academy of Sciences, 1996
- Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindredsNature Genetics, 1995
- Germline p16 mutations in familial melanomaNature Genetics, 1994
- Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locusNature Genetics, 1994